tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.21292/2075-1230-2022-100-11-39-47tiblj-1691Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESЛекарственная чувствительность клинических изолятов Mycobacterium avium complexDrug susceptibility of clinical isolates of Mycobacterium avium complexСтарковаД. А.StarkovaD. A.

Старкова Дарья Андреевна, кандидат биологических наук, старший научный сотрудник лаборатории молекулярной эпидемиологии и эволюционной генетики/старший научный сотрудник лаборатории идентификации патогенов

Тел.: 8 (812) 233-21-49

197101, Санкт-Петербург, ул. Мира, д. 14

Darya A. Starkova, Candidate of Biological Sciences, Senior Researcher of Molecular Epidemiology and Evolutionary Genetics Laboratory, Senior Researcher of Laboratory for Pathogen Identification

Phone: +7 (812) 233-21-49

14, Mira St., St. Petersburg, 197101

dariastarkova13@gmail.comЖуравлевВ. Ю.ZhuravlevV. Yu.

Журавлев Вячеслав Юрьевич, кандидат медицинских наук, ведущий научный сотрудник, координатор направления «Лабораторная диагностика», руководитель лаборатории этиологической диагностики

Тел.: 8 (812) 775-75-55

191036, Санкт-Петербург, Лиговский пр., д. 2-4

Vyacheslav Yu. Zhuravlev, Candidate of Medical Sciences, Leading Researcher, Coordinator of Laboratory Diagnostics Unit, Head of Laboratory for Etiological Diagnostics

Phone: +7 (812) 775-75-55

2-4, Ligovsky Ave., St. Petersburg, 191036

jouravlev-slava@mail.ruСоловьеваН. С.SolovievaN. S.

Соловьева Наталья Сергеевна, кандидат медицинских наук, врач-бактериолог высшей категории, заведующая бактериологической лабораторией

Тел. 8 (812) 775-75-55

191036, Санкт-Петербург, Лиговский пр., д. 2-4

Natalya S. Solovieva, Candidate of Medical Sciences, Bacteriologist of Superior Merit, Head of Bacteriological Laboratory

Phone: +7 (812) 775-75-55

2-4, Ligovsky Ave., St. Petersburg, 191036

baclab@spbniif.ruФБУН «Санкт-Петербургский НИИ эпидемиологии и микробиологии им. Пастера»РоссияPaster St. Petersburg Research Institute of Epidemiology and MicrobiologyRussian FederationФГБУ «Санкт-Петербургский НИИ фтизиопульмонологии» МЗ РФРоссияSt. Petersburg Phthisiopulmonology Research InstituteRussian FederationФГБУ «Санкт-Петербургский НИИ фтизиопульмонологии» МЗ РФРоссияSt. Petersburg Phthisiopulmonology Research Institute,Russian Federation202209122022100113947Copyright © Старкова Д.А., Журавлев В.Ю., Соловьева Н.С., 20222022Старкова Д.А., Журавлев В.Ю., Соловьева Н.С.Starkova D.A., Zhuravlev V.Y., Solovieva N.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/1691Цель исследования

Цель исследования: изучение чувствительности изолятов M. avium и M. intracellulare, выделенных от больных микобактериозом на территории Северо-Западного федерального округа, к антибактериальным препаратам с использованием панелей Sensititre SLOMYCO.

Материалы и методы

Материалы и методы. За период с 2014 по 2020 г. изучены 192 медленнорастущих штамма MAC (164 ‒ M. avium, 28 ‒ M. intracellulare), полученных от ВИЧ-негативных больных микобактериозом легких. Определение лекарственной чувствительности штаммов МАС выполняли с использованием панели из 13 антибактериальных препаратов Sensititre SLOMYCO.

Результаты исследования

Результаты исследования. Из 13 антибактериальных препаратов кларитромицин также оказался наиболее эффективным в отношении как M. avium (67,1%; 110/164), так и M. intracellulare (60,7%; 17/28) (p > 0,05). Доля чувствительных к линезолиду штаммов M. avium и M. intracellulare была высока и составляла 57,3 и 53,5%, к амикацину – 57,3 и 53,5% соответственно.

Из четырех антибактериальных препаратов панели Sensititre SLOMYCO (кларитромицина, моксифлоксацина, линезолида и амикацина), для которых установлены критические концентрации (КК), наиболее эффективным в отношении M. avium и M. intracellulare являлся кларитромицин. Резистентные к антибиотикам изоляты M. avium чаще встречались в группе ранее леченных больных.

The objective

The objective: to study drug susceptibility of M. avium and M. intracellulare isolates received from patients with mycobacteriosis residing in the North Western Federal District using the Sensititre SLOMYCO panels.

Subjects and Methods

Subjects and Methods. From 2014 to 2020, 192 slow-growing MAC strains (164 – M. avium, 28 – M. intracellulare) obtained from HIV-negative patients with pulmonary mycobacteriosis were studied. Drug susceptibility testing of MAC strains was performed using the Sensititre SLOMYCO panel consisting of 13 antibacterial drugs.

Results

Results. Of the 13 antibacterial drugs, clarithromycin was also most effective against both M. avium (67.1%; 110/164) and M. intracellulare (60.7%; 17/28) (p > 0.05). The proportion of M. avium and M. intracellulare strains sensitive to linezolid was high and amounted to 57.3 and 53.5%, as well as to amikacin – 57.3 and 53.5% respectively.

Of the four antibacterial drugs of the Sensititre SLOMYCO panel (clarithromycin, moxifloxacin, linezolid, and amikacin), for which critical concentrations (CC) were established, clarithromycin was the most effective against M. avium and M. intracellulare. Antibiotic-resistant M. avium isolates were more frequent in the group of previously treated patients.

микобактериозMycobacterium aviumM. intracellulareлекарственная чувствительностьSensititre SLOMYCOминимальная ингибирующая концентрацияантибактериальные препаратыmycobacteriosisMycobacterium aviumM. intracellularedrug susceptibilitySensititre SLOMYCOminimum inhibitory concentrationantibacterial drugsReferencesАндреевская С. Н., Ларионова Е. Е., Смирнова Т. Г. и др. Лекарственная чувствительность медленнорастущих нетуберкулезных микобактерий // Туб. и болезни легких. – 2016. – Т. 94, № 4. – С. 43-50. https://doi.org/10.21292/2075-1230-2016-94-4-43-50.Andreevskaya S.N., Larionova E.E., Smirnova T.G. et al. Drug susceptibility of the slow growing non-tuberculous mycobacteria. Tuberculosis and Lung Diseases, 2016, vol. 94, no. 4, pp. 43-50. (In Russ.) https://doi.org/10.21292/2075-1230-2016-94-4-43-50.Старкова Д. А., Журавлев В. Ю., Вязовая А. А. и др. Видовое разно образие нетуберкулезных микобактерий у больных микобактериозом на территориях Северо-Западного федерального округа России // Туб. и болезни легких.– 2019. – Т. 97, № 6. – С. 16-22. https://doi.org/10.21292/2075-1230-2019-97-6-16-22Starkova D.A., Zhuravlev V.Yu., Vyazovaya A.A. et al. Species diversity of non-tuberculous mycobacteria in patients with mycobacteriosis in the North Western Federal District of Russia. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 6, pp. 16-22. (In Russ.) https://doi.org/10.21292/2075-1230-2019-97-6-16-22Черноусова Л. Н., Севастьянова Э. В., Ларионова Е. Е. и др. Федеральные клинические рекомендации по организации и проведению микробиологической и молекулярно-генетической диагностики туберкулеза. ‒ Тверь: ООО «Издательство "Триада"», 2015. ‒ 46 с.Chernousova L.N., Sevastyanova E.V., Larionova E.E. et al. Federalnye klinicheskie rekomendatsii po organizatsii i provedeniyu mikrobiologicheskoy i molekulyarno-geneticheskoy diagnostiki tuberkuleza. [Federal clinical recommendations in organization and implementation of microbiological and molecular-genetic diagnostics of tuberculosis]. Tver, OOO Izdatelstvo Triada Publ., 2015, 46 p.Adachi Y., Tsuyuguchi K., Kobayashi T. et al. Effective treatment for clarithromycin-resistant Mycobacterium avium complex lung disease // J. Infect. Chemother. – 2020. – Vol. 26, № 7. – P. 676-680. doi: 10.1016/j.jiac.2020.02.008.Adachi Y., Tsuyuguchi K., Kobayashi T. et al. Effective treatment for clarithromycin-resistant Mycobacterium avium complex lung disease. J. Infect. Chemother., 2020, vol. 26, no. 7, pp. 676-680. doi: 10.1016/j.jiac.2020.02.008.Brown-Elliott B. A., Iakhiaeva E., Griffith D. E. et al. In vitro activity ofamikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates // J.Clin. Microbiol. –2013. – № 51. – Р. 3389e94.Brown-Elliott B.A., Iakhiaeva E., Griffith D.E. et al. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates. J. Clin. Microbiol., 2013, no. 51, pp. 3389e94.Cho E. H., Huh H. J., Song D. J. et al. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens // J. Infect. Chemother. – 2018. – Vol. 24, № 4. – P. 315-318. doi: 10.1016/j.jiac.2017.10.022.Cho E.H., Huh H.J., Song D.J. et al. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens. J. Infect. Chemother., 2018, vol. 24, no. 4, pp. 315-318. doi: 10.1016/j.jiac.2017.10.022.Clinical Laboratory Standards Institute. Susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes. 3rd ed. CLSI document M24. // Clinical Laboratory Standards Institute. 2018.Clinical Laboratory Standards Institute. Susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes. 3rd ed. CLSI document M24. Clinical Laboratory Standards Institute. 2018.Cowman S., van Ingen J., Griffith D. E. et al. Non-tuberculous mycobacterial pulmonary disease // Eur. Respir. J. – 2019. – Vol. 54, № 1. – Р. 1900250. doi: 10.1183/13993003.00250-2019.Cowman S., van Ingen J., Griffith D.E. et al. Non-tuberculous mycobacterial pulmonary disease. Eur. Respir. J., 2019, vol. 54, no. 1, pp. 1900250. doi: 10.1183/13993003.00250-2019.Huang C. C., Wu M. F., Chen H. C. et al. In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates // J. Microbiol. Immunol. Infect. – 2018. – Vol. 51, №5. – P. 636-643. doi: 10.1016/j.jmii.2017.05.001.Huang C.C., Wu M.F., Chen H.C. et al. In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates. J. Microbiol. Immunol. Infect., 2018, vol. 51, no. 5, pp. 636-643. doi: 10.1016/j.jmii.2017.05.001.Kwon Y. S., Daley C. L., Koh W. J. Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches // Expert Rev. Respir. Med. – 2019. – Vol. 13, № 9. – P. 851-861. doi: 10.1080/17476348.2019.1638765.Kwon Y.S., Daley C.L., Koh W.J. Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches. Expert Rev. Respir. Med., 2019, vol. 13, no. 9, pp. 851-861. doi: 10.1080/17476348.2019.1638765.Li G., Pang H., Guo Q. et al. Antimicrobial susceptibility and MIC distribution of 41 drugs against clinical isolates from China and reference strains of nontuberculous mycobacteria // Int. J. Antimicrob. Agents. - 2017. – Vol. 49, № 3. – P. 364-374. doi: 10.1016/j.ijantimicag.2016.10.024.Li G., Pang H., Guo Q. et al. Antimicrobial susceptibility and MIC distribution of 41 drugs against clinical isolates from China and reference strains of nontuberculous mycobacteria. Int. J. Antimicrob. Agents, 2017, vol. 49, no. 3, pp. 364-374. doi: 10.1016/j.ijantimicag.2016.10.024.Litvinov V., Makarova M., Galkina K. et al. Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system // PLoS One. – 2018. – Vol. 13, № 9. – Р. 0203108. doi: 10.1371/journal.pone.0203108.Litvinov V., Makarova M., Galkina K. et al. Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system. PLoS One, 2018, vol. 13, no. 9, pp. 0203108. doi: 10.1371/journal.pone.0203108.Maurer F. P., Pohle P., Kernbach M. et al. Differential drug susceptibility patterns of Mycobacterium chimaera and other members of the Mycobacterium avium-intracellulare complex // Clin. Microbiol. Infect. – 2019. – Vol. 25, №3.– P. 379.e1-379.e7. doi: 10.1016/j.cmi.2018.06.010.Maurer F.P., Pohle P., Kernbach M. et al. Differential drug susceptibility patterns of Mycobacterium chimaera and other members of the Mycobacterium avium-intracellulare complex. Clin. Microbiol. Infect., 2019, vol. 25, no. 3, pp. 379. e1-379.e7. doi: 10.1016/j.cmi.2018.06.010.Saxena S., Spaink H. P., Forn-Cuní G. Drug resistance in nontuberculous mycobacteria: mechanisms and models // Biology (Basel). – 2021. – Vol. 10, № 2. –96. doi: 10.3390/biology10020096.Saxena S., Spaink H.P., Forn-Cuní G. Drug resistance in nontuberculous mycobacteria: mechanisms and models. Biology (Basel), 2021, vol. 10, no. 2, 96. doi: 10.3390/biology10020096.Schulthess B., Schäfle D., Kälin N. et al. Drug susceptibility distributions of Mycobacterium chimaera and other non-tuberculous mycobacteria // Antimicrob. Agents Chemother. – 2021. – Vol. 65, № 5. – Р. e02131-20. doi: 10.1128/AAC.02131-20.Schulthess B., Schäfle D., Kälin N. et al. Drug susceptibility distributions of Mycobacterium chimaera and other non-tuberculous mycobacteria. Antimicrob. Agents Chemother., 2021, vol. 65, no. 5, pp. e02131-20. doi: 10.1128/AAC.02131-20.Tateishi Y., Ozeki Y., Nishiyama A. et al. Comparative genomic analysis of Mycobacterium intracellulare: implications for clinical taxonomic classification in pulmonary Mycobacterium avium-intracellulare complex disease // BMC Microbiol. – 2021. – Vol. 21, № 1. – Р. 103. doi: 10.1186/s12866-021-02163-9.Tateishi Y., Ozeki Y., Nishiyama A. et al. Comparative genomic analysis of Mycobacterium intracellulare: implications for clinical taxonomic classification in pulmonary Mycobacterium avium-intracellulare complex disease. BMC Microbiol., 2021, vol. 21, no. 1, pp. 103. doi: 10.1186/s12866-021-02163-9.Uchiya K. I., Asahi S., Futamura K. et al. Antibiotic susceptibility andgenotyping of Mycobacterium avium strains that cause pulmonary and disseminated infection // Antimicrob Agents Chemother. – 2018. – Vol. 64, №4. – Р.e02035-17. doi: 10.1128/AAC.02035-17.Uchiya K.I., Asahi S., Futamura K. et al. Antibiotic susceptibility and genotyping of Mycobacterium avium strains that cause pulmonary and disseminated infection. Antimicrob. Agents Chemother., 2018, vol. 64, no. 4, pp. e02035-17. doi: 10.1128/AAC.02035-17.van Ingen J., van der Laan T., Dekhuijzen R. et al. In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands // Int. J. Antimicrob Agents. – 2010. – Vol. 35, № 2. – P. 169-173. doi: 10.1016/j.ijantimicag.2009.09.023.van Ingen J., van der Laan T., Dekhuijzen R. et al. In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands. Int. J. Antimicrob. Agents, 2010, vol. 35, no. 2, pp. 169-173. doi: 10.1016/j.ijantimicag.2009.09.023.Wang D. M., Liao Y., Li Q. F. et al. Drug resistance and pathogenic spectrum of patients coinfected with nontuberculous mycobacteria and human-immunodeficiency virus in Chengdu, China // Chin. Med. J. – 2019. – Vol. 132, № 11. – P. 1293-1297. doi: 10.1097/CM9.0000000000000235.Wang D.M., Liao Y., Li Q.F. et al. Drug resistance and pathogenic spectrum of patients coinfected with nontuberculous mycobacteria and human-immunodeficiency virus in Chengdu, China. Chin. Med. J., 2019, vol. 132, no. 11, pp. 1293-1297. doi: 10.1097/CM9.0000000000000235.Wetzstein N., Kohl T. A., Andres S. et al. Comparative analysis of phenotypic and genotypic antibiotic susceptibility patterns in Mycobacterium avium complex // Int. J. Infect. Dis. – 2020. – № 93. – P. 320-328. doi: 10.1016/j.ijid.2020.02.059.Wetzstein N., Kohl T.A., Andres S. et al. Comparative analysis of phenotypic and genotypic antibiotic susceptibility patterns in Mycobacterium avium complex. Int. J. Infect. Dis., 2020, no. 93, pp. 320-328. doi: 10.1016/j.ijid.2020.02.059.Yamaba Y., Ito Y., Suzuki K. et al. Moxifloxacin resistance and genotyping of Mycobacterium avium and Mycobacterium intracellulare isolates in Japan // J. Infect. Chemother. – 2019. – Vol. 25, № 12. – P. 995-1000. doi: 10.1016/j.jiac.2019.05.028.Yamaba Y., Ito Y., Suzuki K. et al. Moxifloxacin resistance and genotyping of Mycobacterium avium and Mycobacterium intracellulare isolates in Japan. J. Infect. Chemother., 2019, vol. 25, no. 12, pp. 995-1000. doi: 10.1016/j.jiac.2019.05.028.Zhang Z., Pang Y., Wang Y. et al. Differences in risk factors and drug susceptibility between Mycobacterium avium and Mycobacterium intracellulare lung diseases in China // Int. J. Antimicrob. Agents. – 2015. – Vol. 45, № 5. – P. 491-495. doi: 10.1016/j.ijantimicag.2015.01.012.Zhang Z., Pang Y., Wang Y. et al. Differences in risk factors and drug susceptibility between Mycobacterium avium and Mycobacterium intracellulare lung diseases in China. Int. J. Antimicrob. Agents, 2015, vol. 45, no. 5, pp. 491-495. doi: 10.1016/j.ijantimicag.2015.01.012.

The authors declare that there are no conflicts of interest present.